Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Juno Therapeutics, Inc.
483
•Juno Therapeutics, Inc.•October 16, 2020

Juno Therapeutics, Inc. – FDA 483, Oct 16, 2020

Record Details

The FDA Form 483 details observations from an inspection, highlighting several deficiencies in quality control and manufacturing processes.

**Key Violations and Observations:**

* **Inadequate Discrepancy Review (DEV-2019-03442, Critical Classification):** The review of a critical discrepancy involving a (b)(4) result was deficient. * The reliability of the vendor's Certificate of Analysis (CoA) for (b)(4) lots was not established, impacting the quality assessment of previously released lots. * The clinical impact analysis for potential (b)(4) exposure was incomplete, lacking an assessment of adverse events. * A Corrective Action and Preventive Action (CAPA) with effectiveness checks, as per SOP-001151, was not initiated for this critical deviation to address inconsistencies between contract lab and vendor results. Effectiveness checks for implemented corrections were also not conducted. * The investigation did not include an OOS investigation by the (b)(4) vendor, as required by SOP-001145, to validate their assay results.

* **Improper Classification of Investigations:** Several Notice of Events (NOEs) were not classified as Deviations, despite potential product impact: * DEV-2020-02527: Suspected (b)(4) during (b)(4) of Lot (

Company
Juno Therapeutics, Inc.
Inspection date
October 16, 2020
Product type
Biologics
Office
Division of Manufacturing and Product Quality
People
  • Eileen A. Liu
  • Prabhu P. Raju (Program Expert for Advanced Manufacturing )
View Company Profile

ID · 2752e95f-f049-4f3d-8b35-a736c090e366

Violation Codes10
21 CFR 331(c)21 CFR 211.100(b)21 CFR 211.165(a)21 CFR 211.67(b)21 CFR 211.42(c)(10)(v)21 CFR 211.17621 CFR 211.160(a)21 CFR 211.42(c)(10)(vi)21 U.S.C. 324(a)(4)FD&C Act 501(b)

Full citation text and observation details available on the Dashboard.

Other documents for Juno Therapeutics, Inc.
  • 483 - 2023-09-20September 20, 2023
  • EIR - 2020-10-16October 16, 2020
  • 483_RESPONSE - 2020-10-16October 16, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Juno Therapeutics, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.